We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.

U.S. P2Y12 INHIBITORS MARKET ANALYSIS

U.S. P2Y12 Inhibitors Market, by Drug (Clopidogrel, Ticlopidine, Ticagrelor, Prasugrel, Cangrelor, and Others), by Route of Administration (Oral and Intravenous), by Application (Angioplasty, Arterial Thrombosis, Percutaneous Coronary Interventions, Myocardial Infarction, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Mar 2022
Code : CMI4983
Pages :156
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Key Players

Major players operating in the U.S. P2Y12 inhibitors market include Mylan N.V., Bristol-Myers Squibb, Dr Reddy's Laboratories, Teva Pharmaceuticals USA, Inc., AstraZeneca, Genentech, Eli Lilly and Company, Panacea Biotec, CHIESI USA, Inc., Lupin, Cipla, and Biocon.